Publications by authors named "Jeremy Dennison"

Claim this Profile
I
Impact of updated regulatory guidelines on study results in contemporary uncomplicated urinary tract infection clinical trials and implications for trial conduct and drug development: a comparative analysis with EAGLE-2 and EAGLE-3.
Florian Wagenlehner, Keith S Kaye, David A Talan, Amanda J Sheets, Nicole E Scangarella-Oman, Jeremy Dennison

Contemp Clin Trials Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and activity of gepotidacin against bacterial uropathogens, including drug-resistant phenotypes, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3).
Nicole E Scangarella-Oman, Deborah L Butler, John Breton, Derrek Brown, Cara Kasapidis, Jeremy Dennison

Antimicrob Agents Chemother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vertical transmission of chronic wasting disease in free-ranging white-tailed deer populations.
Audrey M Sandoval, Amy V Nalls, Erin E McNulty, Nathaniel D Denkers, Devon J Trujillo, Jeremy S Dennison

Sci Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary: efficacy and safety of gepotidacin, a new oral antibiotic, compared with nitrofurantoin, a commonly used oral antibiotic, for treating uncomplicated urinary tract infection.
Florian Wagenlehner, Caroline R Perry, Thomas M Hooton, Nicole E Scangarella-Oman, Helen Millns, Jeremy Dennison

Future Microbiol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vertical transmission of chronic wasting disease in free-ranging white-tailed deer populations.
Audrey M Sandoval, Amy V Nalls, Erin E McNulty, Nathaniel D Denkers, Devon J Trujillo, Jeremy S Dennison

bioRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.
Florian Wagenlehner, Caroline R Perry, Thomas M Hooton, Nicole E Scangarella-Oman, Helen Millns, Jeremy Dennison

Lancet· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [C]PHNO PET.
Eugenii A Rabiner, Tolga Uz, Ayla Mansur, Terry Brown, Grace Chen, Jeremy M T J Dennison

Neuropsychopharmacology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and ADME Characterization of Intravenous and Oral [C]-Linerixibat in Healthy Male Volunteers.
Maciej J Zamek-Gliszczynski, David Kenworthy, David A Bershas, Mitesh Sanghvi, Adrian I Pereira, Jeremy M T J Dennison

Drug Metab Dispos· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects.
Jean-Yves Gillon, Jeremy Dennison, Frans van den Berg, Sophie Delhomme, Karen Dequatre Cheeseman

Br J Clin Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONO-7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study.
Dominic Beale, Jeremy Dennison, Malcolm Boyce, Francesca Mazzo, Naoki Honda

Br J Clin Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study.
Etienne F Dumont, Amanda J Oliver, Chris Ioannou, Julia Billiard, Jeremy Dennison

Antimicrob Agents Chemother· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers.
Jeremy Dennison, Adeep Puri, Steven Warrington, Takamasa Endo, Temitope Adeloye

Clin Pharmacol Drug Dev· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Temitope Adeloye, Omair Sahgal, Adeep Puri, Steve Warrington, Takamasa Endo, Jeremy Dennison

Clin Pharmacol Drug Dev· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis